Povetacicept PDUFA date: FDA decision expected November 30, 2026

The FDA is expected to decide on Povetacicept from Vertex Pharmaceuticals Incorporated in Primary Membranous Nephropathy by the PDUFA target action date of November 30, 2026. For IgA Nephropathy. BLA accepted. AI-extracted from: Vertex Announces US FDA Acceptance of Biologics License Application for Accelera

A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.